229,619 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by NEXTBio Capital Management LP

NEXTBio Capital Management LP bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 229,619 shares of the company’s stock, valued at approximately $20,055,000. Protagonist Therapeutics accounts for about 11.8% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 2nd largest position.

Several other large investors have also added to or reduced their stakes in the business. Farallon Capital Management LLC grew its stake in Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after purchasing an additional 24,000 shares during the period. Vanguard Group Inc. grew its stake in Protagonist Therapeutics by 27.2% in the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after acquiring an additional 1,156,461 shares during the period. State Street Corp grew its stake in Protagonist Therapeutics by 18.5% in the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after acquiring an additional 500,924 shares during the period. UBS Group AG grew its stake in Protagonist Therapeutics by 46.1% in the fourth quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock valued at $241,934,000 after acquiring an additional 874,013 shares during the period. Finally, Wellington Management Group LLP grew its stake in Protagonist Therapeutics by 83.9% in the third quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company’s stock valued at $126,778,000 after acquiring an additional 870,708 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 0.0%

PTGX stock opened at $109.78 on Friday. Protagonist Therapeutics, Inc. has a twelve month low of $49.38 and a twelve month high of $111.78. The stock’s 50 day moving average is $101.71 and its 200-day moving average is $93.22. The firm has a market capitalization of $7.06 billion, a PE ratio of -60.65 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The company had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. On average, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on PTGX shares. Wall Street Zen raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wolfe Research started coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Truist Financial raised their price objective on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Finally, Citigroup reissued an “outperform” rating on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $115.21.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 15,000 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the completion of the sale, the insider owned 84,115 shares of the company’s stock, valued at approximately $8,814,410.85. This trade represents a 15.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 272,345 shares of company stock valued at $27,676,386 in the last quarter. 5.19% of the stock is owned by company insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.